Neurizon Therapeutics Limited
NUZ.ASXHealth Care
To develop its own drug discovery intellectual property for the treatment of different types of neurological diseases
Market Data
$0.062
-0.0%$46.3M
-100000.0x
$-0.029
0.00%
-0.5%
Latest Earnings
Appendix 4D - Half-year Financial Report - 31 December 2025
25 February 2026
Neurizon Therapeutics reduced its half-year loss to $5.5M (down 23.9% from $7.3M), driven by significantly higher R&D tax incentive income of $6.0M. The company achieved key clinical and regulatory milestones including FDA lifting of clinical hold on lead drug NUZ-001 and securing an exclusive global licensing agreement with Elanco, positioning it well for participation in the HEALEY ALS Platform Trial. Key points: FDA lifted clinical hold on NUZ-001, clearing path for participation in HEALEY ALS Platform Trial; Exclusive global licensing agreement with Elanco provides worldwide rights to monepantel and extensive non-clinical safety/manufacturing data; Positive Phase 1 Open-Label Extension results showed favorable long-term safety profile with exploratory signals of efficacy and survival
Recent Announcements
Appendix 4D - Half-year Financial Report - 31 December 2025
Neurizon Therapeutics reduced its half-year loss to $5.5M (down 23.9% from $7.3M), driven by significantly higher R&D tax incentive income of $6.0M. The company achieved key clinical and regulatory milestones including FDA lifting of clinical hold on lead drug NUZ-001 and securing an exclusive global licensing agreement with Elanco, positioning it well for participation in the HEALEY ALS Platform Trial. Key points: FDA lifted clinical hold on NUZ-001, clearing path for participation in HEALEY ALS Platform Trial; Exclusive global licensing agreement with Elanco provides worldwide rights to monepantel and extensive non-clinical safety/manufacturing data; Positive Phase 1 Open-Label Extension results showed favorable long-term safety profile with exploratory signals of efficacy and survival
Get real-time alerts for NUZ
Receive AI-powered earnings summaries and instant notifications when Neurizon Therapeutics Limited releases results.
Register Free